Literature DB >> 15834987

Route of infection in melioidosis.

Jodie L Barnes, Natkunam Ketheesan.   

Abstract

Entities:  

Mesh:

Year:  2005        PMID: 15834987      PMCID: PMC3320332          DOI: 10.3201/eid1104.041051

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Melioidosis is an emerging tropical infectious disease, the incidence of which is unknown in many developing countries because of the lack of diagnostic tests and medical practitioners' lack of awareness of the disease. It is a potentially fatal disease caused by the soil bacterium Burkholderia pseudomallei. Clinical manifestations, severity, and duration of B. pseudomallei infection vary greatly (). Melioidosis develops after subcutaneous infection, inhalation, or ingestion of contaminated particles or aerosols. Infection has occurred after near-drowning accidents (–) and transmission of B. pseudomallei in drinking water (). The route of B. pseudomallei infection is at least 1 of the factors that influences disease outcome, thus contributing to the broad spectrum of clinical signs associated with melioidosis. Researchers use different routes of delivery of B. pseudomallei in experimental models to study the pathogenesis of the disease and the induction of host protection. Infection by different routes exposes a pathogen to different components of the host immune system and may subsequently influence disease outcome. Despite this difference, no comprehensive investigation has compared the pathogenesis of melioidosis established by different routes of infection. Following intravenous (IV) injection, BALB/c mice are highly susceptible, and C57BL/6 mice are relatively resistant to B. pseudomallei infection (). Using this murine model, we compared the pathogenesis of B. pseudomallei infection after introducing the bacterium by IV, intraperitoneal (IP), intranasal, oral, and subcutaneous (SC) routes of infection. The virulence of 2 B. pseudomallei strains (NCTC 13178 and NCTC 13179) was compared in BALB/c and C57BL/6 mice by using a modified version of the Reed & Meunch (1938) method. Compared to BALB/c mice, C57BL/6 mice are less susceptible to B. pseudomallei infection, regardless of the portal of entry, thus validating the model of differential susceptibility for various routes of infection (Table). However, as demonstrated by others (–), C57BL/6 mice are not completely resistant to infection by B. pseudomallei. Systemic melioidosis can be generated in C57BL/6 mice by using different routes of infection, if a high dose is used. When injected IV into BALB/c mice, NCTC 13178 is highly virulent since the 50% lethal dose (LD50) is <10 CFU. However, if BALB/c mice are injected SC with NCTC 13178, the LD50 value increases 100-fold to 1 x 103 CFU. This value is equivalent to the LD50 of the less virulent NCTC 13179 delivered SC The results emphasize that virulence depends on the route of infection.
Table

Ten-day LD50* values (given in CFU) after intravenous, intraperitoneal, subcutaneous, intranasal, or oral introduction of NCTC 13178 or NCTC 13179 strains of Burholderia pseudomallei into BALB/c or C57BL/6 mice

Route of infectionNCTC 13178
NCTC 13179
BALB/cC57BL/6BALB/cC57BL/6
Intravenous<105 x 1039 x 1036 x 106
Intraperitoneal1.2 x 1019.7 x 1034.7 x 1052.1 x 107
Subcutaneous1 x 1039 x 1059 x 102>108
Intranasal†1.4 x 1021.8 x 1031.9 x 106>108
Oral‡7.2 x 1031.8 1064.8 x 106>108

*50% lethal dose.
†20 µL of challenge dose was introduced intranasally onto the nostrils of the mice by using a pipette tip.
‡20 µL of challenge dose was introduced orally to the back of the throat of the mice by using a pipette tip.

*50% lethal dose.
†20 µL of challenge dose was introduced intranasally onto the nostrils of the mice by using a pipette tip.
‡20 µL of challenge dose was introduced orally to the back of the throat of the mice by using a pipette tip. The pathogenesis of B. pseudomallei NCTC 13178 infection was compared after infection by the IV, IP, SC, intranasal, and oral routes. BALB/c and C57BL/6 mice were administered 570 CFU (equivalent to 60 x LD50 delivered IV) or 3 x 105 CFU (equivalent to 60 x LD50 delivered IV), respectively. At 1, 2, and 3 days postinfection, bacterial loads were measured in blood, spleen, liver, lungs, lymph nodes (right and left axillary and inguinal), and brain by using methods described previously (). A tropism for spleen and liver was demonstrated following infection by each of the 5 routes. B. pseudomallei could be detected in the tissues of IV- and IP-infected mice earlier and in higher numbers than in those of intranasally and orally-infected mice, despite the fact that all mice received equal numbers of bacteria. This finding reflects differences in the innate immune response, depending on the route of infection. Bacterial numbers in mice infected by the IV or IP route reached >106 CFU by day 2 postinfection, which indicates a failure of the innate immune response to control infection, leading to overwhelming sepsis and death. Bacterial loads in tissues after challenge with a lethal dose of highly virulent NCTC 13178 did not indicate any tropism for the lung after intranasal infection. As early as day 1, bacterial loads were greatest in the liver and spleen, not lungs, of C57BL/6 and BALB/c mice following intranasal challenge. This finding suggests a very early systemic spread of B. pseudomallei from the lungs to other organs. Bacteria were detected in the brains of all mice after infection by either the IV, IP, intranasal, or oral route. Colonies recovered from the brains of C57BL/6 mice infected by the intranasal or oral routes were mucoid in appearance. In comparison, bacteria recovered from brains of C57BL/6 mice that were challenged by the IV or IP route demonstrated the characteristic wrinkled shape on Ashdown agar and may have been a consequence of the overwhelming septicemia that spilled over to all organs. Variation in colonial morphology of B. pseudomallei has been documented previously (), and biofilm formation may be an adaptation of B. pseudomallei that enables it to evade host immune responses or to survive within unfavorable environments (,). The variation in colonial morphology on Ashdown agar observed in bacteria isolated from brains of C57BL/6 mice infected by the intranasal or oral route may reflect a change to biofilm formation of B. pseudomallei in this tissue. In summary, the results of this study reiterate the validity of the mouse model for differential susceptibility to B. pseudomallei, regardless of the route of infection. The data also emphasize that virulence depends on the portal of entry of B. pseudomallei. Researchers should, therefore, be particularly cautious when comparing and extrapolating data from studies that use different methods of infection.
  10 in total

1.  Enhancement of virulence of Malleomyces pseudomallei.

Authors:  C NIGG; J RUCH; E SCOTT; K NOBLE
Journal:  J Bacteriol       Date:  1956-05       Impact factor: 3.490

2.  Case report: septicemic melioidosis following near drowning.

Authors:  P Pruekprasert; S Jitsurong
Journal:  Southeast Asian J Trop Med Public Health       Date:  1991-06       Impact factor: 0.267

3.  Dry-season outbreak of melioidosis in Western Australia.

Authors:  T J Inglis; S C Garrow; C Adams; M Henderson; M Mayo
Journal:  Lancet       Date:  1998-11-14       Impact factor: 79.321

4.  BALB/c and C57Bl/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis.

Authors:  A K Leakey; G C Ulett; R G Hirst
Journal:  Microb Pathog       Date:  1998-05       Impact factor: 3.738

5.  Atypical morphological characteristics and surface antigen expression of Burkholderia pseudomallei in naturally infected human synovial tissues.

Authors:  R Nanagara; K Vipulakorn; S Suwannaroj; H R Schumacher
Journal:  Mod Rheumatol       Date:  2000-09       Impact factor: 3.023

6.  Model of differential susceptibility to mucosal Burkholderia pseudomallei infection.

Authors:  Boping Liu; Ghee Chong Koo; Eu Hian Yap; Kim Lee Chua; Yunn-Hwen Gan
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

7.  Characterization of a murine model of melioidosis: comparison of different strains of mice.

Authors:  I Hoppe; B Brenneke; M Rohde; A Kreft; S Häussler; A Reganzerowski; I Steinmetz
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

8.  Pseudomonas pseudomallei infection from drowning: the first reported case in Taiwan.

Authors:  N Lee; J L Wu; C H Lee; W C Tsai
Journal:  J Clin Microbiol       Date:  1985-09       Impact factor: 5.948

Review 9.  Melioidosis: review and update.

Authors:  A Leelarasamee; S Bovornkitti
Journal:  Rev Infect Dis       Date:  1989 May-Jun

10.  Electron microscopy study of the mode of growth of Pseudomonas pseudomallei in vitro and in vivo.

Authors:  M Vorachit; K Lam; P Jayanetra; J W Costerton
Journal:  J Trop Med Hyg       Date:  1995-12
  10 in total
  39 in total

1.  Pathogenicity of high-dose enteral inoculation of Burkholderia pseudomallei to mice.

Authors:  T Eoin West; Nicolle D Myers; Direk Limmathurotsakul; H Denny Liggitt; Narisara Chantratita; Sharon J Peacock; Shawn J Skerrett
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

2.  Migration of dendritic cells facilitates systemic dissemination of Burkholderia pseudomallei.

Authors:  Natasha L Williams; Jodie L Morris; Catherine M Rush; Natkunam Ketheesan
Journal:  Infect Immun       Date:  2014-07-28       Impact factor: 3.441

3.  Hydrological connectivity and Burkholderia pseudomallei prevalence in wetland environments: investigating rice-farming community's risk of exposure to melioidosis in North-East Thailand.

Authors:  C Joon Chuah; Esther K H Tan; Rasana W Sermswan; Alan D Ziegler
Journal:  Environ Monit Assess       Date:  2017-05-23       Impact factor: 2.513

4.  Burkholderia pseudomallei triggers altered inflammatory profiles in a whole-blood model of type 2 diabetes-melioidosis comorbidity.

Authors:  Jodie Morris; Natasha Williams; Catherine Rush; Brenda Govan; Kunwarjit Sangla; Robert Norton; Natkunam Ketheesan
Journal:  Infect Immun       Date:  2012-04-02       Impact factor: 3.441

5.  Delayed activation of host innate immune pathways in streptozotocin-induced diabetic hosts leads to more severe disease during infection with Burkholderia pseudomallei.

Authors:  Chui-Yoke Chin; Denise M Monack; Sheila Nathan
Journal:  Immunology       Date:  2012-04       Impact factor: 7.397

6.  Genome-wide expression analysis of Burkholderia pseudomallei infection in a hamster model of acute melioidosis.

Authors:  Apichai Tuanyok; Marina Tom; John Dunbar; Donald E Woods
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

7.  Impaired early cytokine responses at the site of infection in a murine model of type 2 diabetes and melioidosis comorbidity.

Authors:  Kelly A Hodgson; Brenda L Govan; Anna K Walduck; Natkunam Ketheesan; Jodie L Morris
Journal:  Infect Immun       Date:  2012-12-03       Impact factor: 3.441

8.  Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine.

Authors:  Ediane B Silva; Andrew Goodyear; Marjorie D Sutherland; Nicole L Podnecky; Mercedes Gonzalez-Juarrero; Herbert P Schweizer; Steven W Dow
Journal:  Infect Immun       Date:  2013-10-07       Impact factor: 3.441

9.  Inhalation of Burkholderia thailandensis results in lethal necrotizing pneumonia in mice: a surrogate model for pneumonic melioidosis.

Authors:  T Eoin West; Charles W Frevert; H Denny Liggitt; Shawn J Skerrett
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-12       Impact factor: 2.184

10.  BPSS1504, a cluster 1 type VI secretion gene, is involved in intracellular survival and virulence of Burkholderia pseudomallei.

Authors:  Verena Hopf; André Göhler; Kristin Eske-Pogodda; Antje Bast; Ivo Steinmetz; Katrin Breitbach
Journal:  Infect Immun       Date:  2014-03-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.